Recent advancements in vitiligo treatment have reshaped the field, offering new hope for patients. Dr. Seemal Desai highlights key developments, including the FDA-approved topical ruxolitinib 1.5% cream, which has become a breakthrough for repigmenting nonsegmental vitiligo. Clinical trials (TRuE-V1 and TRuE-V2) showed that nearly one-third of patients achieved significant repigmentation after 24 weeks, and 15% had complete or near-complete facial repigmentation.
In addition to topical treatments, emerging oral JAK inhibitors, like upadacitinib and povorcitinib, show promise. Upadacitinib demonstrated sustained repigmentation improvements by week 52 in a 52-week trial. Povorcitinib trials also showed strong repigmentation results and maintained efficacy up to week 76 post-treatment. These advancements underscore the growing possibilities in vitiligo treatment, with further progress anticipated in 2024 and beyond.
